Ascendis Pharma A (ASND) Cost of Revenue (2021 - 2026)

Ascendis Pharma A (ASND) has 6 years of Cost of Revenue data on file, last reported at $20.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 11.29% year-over-year to $20.5 million; the trailing twelve-month figure through Mar 2026 stood at $109.7 million (up 88.96% YoY), and the FY2025 full-year result was $136.2 million, up 174.87% from the prior year.
• Cost of Revenue declined to $20.5 million in Q1 2026, from $27.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $35.6 million in Q2 2025 to a low of $1.2 million in Q2 2022.
• A 5-year average of $13.9 million and a median of $12.3 million in 2024 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue soared 1114.91% in 2023 and declined 28.42% in 2024, its largest moves.
• Tracing ASND's Cost of Revenue over 5 years: stood at $5.2 million in 2022, then jumped by 301.47% to $20.9 million in 2023, then decreased by 28.42% to $15.0 million in 2024, then soared by 83.31% to $27.5 million in 2025, then slipped by 25.35% to $20.5 million in 2026.
• Business Quant data shows ASND's Cost of Revenue at $20.5 million in Q1 2026, $27.5 million in Q4 2025, and $26.1 million in Q3 2025.